Targeting astrocytes Ameliorates neurologic changes in a mouse model of Alzheimer's disease

Journal of Neuroscience

Volumn 32, Issue 46, 2012, Pages 16129-16140

  Furman, Jennifer L ^a   Sama, Diana M ^a   Gant, John C ^a   Beckett, Tina L ^b   Murphy, M Paul ^a,b   Bachstetter, Adam D ^b   van Eldik, Linda J ^a,b   Norris, Christopher M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CALCINEURIN; CALCINEURIN INHIBITOR; GLIAL FIBRILLARY ACIDIC PROTEIN; PARVOVIRUS VECTOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VIVIT PEPTIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; AVOIDANCE BEHAVIOR; CELL STRUCTURE; COGNITION; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; WESTERN BLOTTING;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; AVOIDANCE LEARNING; BLOTTING, WESTERN; BRAIN; CALCINEURIN; CELLS, CULTURED; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY POSTSYNAPTIC POTENTIALS; GENE TRANSFER TECHNIQUES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LONG-TERM POTENTIATION; MICE; MICE, TRANSGENIC; NEURONS; NFATC TRANSCRIPTION FACTORS; OLIGOPEPTIDES; SIGNAL TRANSDUCTION;

EID: 84869016768     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2323-12.2012     Document Type: Article

References (64)

1. Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H 3rd, Kraner SD, Norris CM (2009) Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 29:12957-12969.
2. Agostinho P, Lopes JP, Velez Z, Oliveira CR (2008) Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem Int 52:1226-1233.
3. Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP (2010) BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem 112:1045-1053.
4. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
5. Aramburu J, Yaffe MB, López-Rodríguez C, Cantley LC, Hogan PG, Rao A (1999) Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285:2129-2133.
6. Bachstetter AD, Norris CM, Sompol P, Wilcock DM, Goulding D, Neltner JH, St Clair D, Watterson DM, van Eldik LJ (2012) Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits agedependent progression of Alzheimer's disease-related pathology. J Neurosci 32:10201-10210.
7. Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, Johnson EM Jr, Olanow CW, Mufson EJ, Kordower JH (2011) Bioactivity of AAV2- neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 26:27-36.
8. Canellada A, Ramirez BG, Minami T, Redondo JM, Cano E (2008) Calcium/calcineurin signaling in primary cortical astrocyte cultures: Rcan1-4 and cyclooxygenase-2 as NFAT target genes. Glia 56:709-722.
9. Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A (2012) Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 53:37-46.
10. Celsi F, Svedberg M, Unger C, Cotman CW, Carrì MT, Ottersen OP, Nordberg A, Torp R (2007) Beta-amyloid causes downregulation of calcineurin in neurons through induction of oxidative stress. Neurobiol Dis 26: 342-352.
11. Cho HJ, Jin SM, Youn HD, Huh K, Mook-Jung I (2008) Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling. Aging Cell 7:137-147.
12. Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, Mook-Jung I (2009) RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 23:2639-2649.
13. Crabtree GR, Olson EN (2002) NFAT signaling: choreographing the social lives of cells. Cell [Suppl] 109:S67-S79.
14. Daulatzai MA (2010) Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease. J Alzheimers Dis 20: 355-367.
15. Di Filippo M, Sarchielli P, Picconi B, Calabresi P (2008) Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immunecentred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 29:402-412.
16. Dineley KT, Kayed R, Neugebauer V, Fu Y, Zhang W, Reese LC, Taglialatela G (2010) Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res 88:2923-2932.
17. DiPrimio N, McPhee SW, Samulski RJ (2010) Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. Curr Opin Mol Ther 12:553-560.
18. Fernandez AM, Fernandez S, Carrero P, Garcia-Garcia M, Torres-Aleman I (2007) Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J Neurosci 27: 8745-8756.
19. Fernandez AM, Jimenez S, Mecha M, Dávila D, Guaza C, Vitorica J, Torres-Aleman I (2012) Regulation of the phosphatase calcineurin by insulinlike growth factor I unveils a key role of astrocytes in Alzheimer's pathology. Mol Psychiatry 17:705-718.
20. Foster TC (2002) Regulation of synaptic plasticity in memory and memory decline with aging. Prog Brain Res 138:283-303.
21. 2+-dependent processes: relation to hippocampal synaptic plasticity. Hippocampus 7:602-612.
22. Fuller S, Münch G, Steele M (2009) Activated astrocytes: a therapeutic target in Alzheimer's disease? Expert Rev Neurother 9:1585-1594.
23. Furman JL, Artiushin IA, Norris CM (2010) Disparate effects of serum on basal and evoked NFAT activity in primary astrocyte cultures. Neurosci Lett 469:365-369.
24. Hong HS, Hwang JY, Son SM, Kim YH, Moon M, Inhee MJ (2010) FK506 reduces amyloid plaque burden and induces MMP-9 in AbetaPP/PS1 double transgenic mice. J Alzheimers Dis 22:97-105.
25. Horsley V, Pavlath GK (2002) NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol 156:771-774.
26. Hudry E, Wu HY, Arbel-Ornath M, Hashimoto T, Matsouaka R, Fan Z, Spires-Jones TL, Betensky RA, Bacskai BJ, Hyman BT (2012) Inhibition of the NFAT pathway alleviates amyloid-_ neurotoxicity in a mouse model of Alzheimer's disease. J Neurosci 32:3176-3192.
27. +/calcineurin-NFAT-mediated signaling. Mol Cells 18:1-9.
28. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159-170.
29. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097-2105.
30. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, Rowan M, Cleary J, Wallis RA, Sun GY, Cole G, Frautschy S, Anwyl R, Ashe KH (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131:651-664.
31. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25:11693-11709.
32. Lee CY, Landreth GE (2010) The role of microglia in amyloid clearance from the AD brain. J Neural Transm 117:949-960.
33. Lee Y, Messing A, Su M, Brenner M (2008) GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia 56:481-493.
34. Li H, Rao A, Hogan PG (2011) Interaction of calcineurin with substrates and targeting proteins. Trends Cell Biol 21:91-103.
35. Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX (2005) Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem 280:37755-37762.
36. Malenka RC (2003) The long-term potential of LTP. Nat Rev Neurosci 4:923-926.
37. Marchetti C, Marie H (2011) Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? Rev Neurosci 22:373-402.
38. Mathis DM, Furman JL, Norris CM (2011) Preparation of acute hippocampal slices from rats and transgenic mice for the study of synaptic alterations during aging and amyloid pathology. J Vis Exp pii:2330.
39. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
40. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191-199.
41. Mohmmad Abdul H, Baig I, Levine H 3rd, Guttmann RP, Norris CM (2011) Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta in primary cell culture. Aging Cell 10:103-113.
42. Morgan D (2011) Immunotherapy for Alzheimer's disease. J Int Med 269: 54-63.
43. Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW (2012) Mild cognitive impairment: pathology and mechanisms. Acta Neuropathologica 123: 13-30.
44. Munoz L, Ammit AJ (2010) Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 58:561-568.
45. Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, St Clair DK, LeVine H 3rd, Keller JN (2007) Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 27:301-311.
46. Nagamoto-Combs K, Combs CK (2010) Microglial phenotype is regulated by activity of the transcription factor, NFAT (nuclear factor of activated T cells). J Neurosci 30:9641-9646.
47. Norris CM, Scheff SW (2009) Recovery of afferent function and synaptic strength in hippocampal CA1 following traumatic brain injury. J Neurotrauma 26:2269-2278.
48. 2+ channels. J Neurosci 18:3171-3179.
49. Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, Porter NM, Landfield PW, Kraner SD (2005) Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. J Neurosci 25:4649-4658.
50. 2+ channels with aging. Neurobiol Aging 31:328-338.
51. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129-10140.
52. Owen JB, Di Domenico F, Sultana R, Perluigi M, Cini C, Pierce WM, Butterfield DA (2009) Proteomics-determined differences in the concanavalin-Afractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J Proteome Res 8:471-482.
53. Reese LC, Zhang W, Dineley KT, Kayed R, Taglialatela G (2008) Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell 7:824-835.
54. Rodríguez JJ, Olabarria M, Chvatal A, Verkhratsky A (2009) Astroglia in dementia and Alzheimer's disease. Cell Death Differ 16:378-385.
55. Rossner S, Apelt J, Schliebs R, Perez-Polo JR, Bigl V (2001) Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J Neurosci Res 64:437-446.
56. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R (2007) Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans 35:1219-1223.
57. Sama MA, Mathis DM, Furman JL, Abdul HM, Artiushin IA, Kraner SD, Norris CM (2008) Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. J Biol Chem 283:21953-21964.
58. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-_ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of _-secretase. J Neurosci 23:9796-9804.
59. Sastre M, Klockgether T, Heneka MT (2006) Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 24:167-176.
60. Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, Arvanitakis Z (2006) Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 27:252-261.
61. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
62. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK (2007) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117:1595-1604.
63. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866-2875.
64. Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, Bowman AB, Aschner M (2011) Role of astrocytes in brain function and disease. Toxicol Pathol 39:115-123.